Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas
  
lung cancer
Akeso/Summit bispecific antibody demonstrates PFS in lung cancer setting • Source: Shutterstock

More from Strategy

More from Therapy Areas